Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 15.3 Billion Yen to Be Allocated to 30 Projects to Promote R&D in Field of Healthcare
June 16, 2017
- MHLW Panel Recommends Moving Ahead with Discussions toward Easing Regulations on Export of Blood Products
June 16, 2017
- MHLW Tries to Give Full Picture of Envisaged “CEA” Scheme with Hypothetical Drug: Chuikyo
June 15, 2017
- 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
- Daiichi Sanko Espha Skips June Listing for Rezaltas, Gracevit AGs
June 15, 2017
- Chuikyo Reps Agree on Revisiting Discrepancy Rate Cutoff for Price Maintenance Premium
June 15, 2017
- Chuikyo Members Want to Stick to Pilot-Based Premium, at Odds with Industry
June 15, 2017
- (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
- Chuikyo OKs Plan for FY2017 Drug Price Survey
June 14, 2017
- Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
- PMDA Provides Relief for Over 100 Health Damage Cases Tied to HPV Vaccines: FY2016
June 13, 2017
- MHLW Panel Gives Thumbs-Up for Nusinersen, Tenelia-Canaglu Combo
June 12, 2017
- MHLW Study Group on Counterfeit Drugs to Discuss Issues such as GDP Later This Fiscal Year
June 12, 2017
- Govt’s Regulatory Reform Plan Embraces Review of 14-Day Prescription Limit
June 12, 2017
- MHLW Study Group Compile Draft Interim Report on Preventing Distribution of Counterfeit Drugs
June 12, 2017
- Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
- MHLW Issues Notification on New Format for Package Inserts
June 9, 2017
- MHLW Study Puts Global Biosimilar Market at 1-3 Trillion Yen in 2020
June 8, 2017
- Govt to Erase Reference Pricing from Honebuto Policy, though Proposal Still Alive
June 8, 2017
- Tweaking Likely for Honebuto Wording on Reference Pricing, Integration of Gx Price Bands
June 7, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…